Bristol Myers Squibb Announced The Final Analysis Of Overall Survival From The Phase 3 Checkmate -816 Study, Which Evaluated Opdivo (Nivolumab) In Combination With Platinum-doublet Chemotherapy As A Neoadjuvant Treatment For Adult Patients With Resectable